Mucosal healing in Crohn's disease: new insights. (3rd May 2020)

• Record Type: Journal Article
• Authors: Cucchiara, Salvatore; D'Arcangelo, Giulia; Isoldi, Sara; Aloi, Marina; Stronati, Laura
• Is Part Of: Expert review of gastroenterology & hepatology. Volume 14:Number 5(2020)
• Page Start: 335
• Page End: 345
• Publication Date: 2020-05-03
• Subjects: Biologics -- bowel damage -- Crohn's disease -- inflammatory bowel disease -- mucosal healing -- treat-to-target; Gastroenterology -- Periodicals; Liver -- Diseases -- Periodicals; 616.3
• DOI: 10.1080/17474124.2020.1759416
• Languages: English
• ISSNs: 1747-4124

Abstract

ABSTRACT: Introduction: Traditional management of patients with Crohn's disease includes symptoms and quality of life improvement. With the advent of biological agents, mucosal healing has become an achievable goal, documented through endoscopy. However, due to the transmural nature of inflammation, the prevention of bowel damage should be included in the aims of a targeted therapeutic strategy. Areas covered: Updated literature has been searched in PubMed from 2008 to 2020. This review focuses on the state of the art in the innovative therapeutic goals in Crohn's disease, also considering still controversial aspects and future research topics in the management of Crohn's disease. Expert opinion: Although a widely agreed view supports the notion that mucosal healing and bowel damage control may promote beneficial outcomes (i.e. reduction in hospitalization and surgical rates, avoidance of steroids), long-term robust data are still missing. On the other hand, the development of -omics techniques has expanded our knowledge of the pathogenetic mechanism underlying inflammatory bowel disease and opened up new horizons in precision or personalized medicine.